Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations

Cutaneous squamous cell carcinoma (cSCC) may develop in patients with dysregulated immune activation (pre-existing autoimmune diseases or immunosuppression due to hematopoietic/solid organ transplant recipients), patients with a compromised immune function (long-term immunosuppression), and patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossi, Paolo, Lorini, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609951/
https://www.ncbi.nlm.nih.gov/pubmed/34877078
http://dx.doi.org/10.5826/dpc.11S2a170S

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609951/
https://www.ncbi.nlm.nih.gov/pubmed/34877078
http://dx.doi.org/10.5826/dpc.11S2a170S

Ejemplares similares